ASGN
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
08/19/2026
Back to search
Official data from USPTO
IMBRIUM THERAPEUTICS
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: United States
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
08/19/2026
Trademark type
Combined
Nice classes
5
Filing date
06/14/2019
Registration date
06/09/2020
Expiration date
-
Complete case details
Structured fields from the responsible authority and the official record.
Status date
06/09/2020
Last transaction
08/19/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Filing basis
Intent to use
First use anywhere
09/24/2019
First use in commerce
09/24/2019
Drawing code
3
Owner type
16
Owner location
STAMFORD, CT, US
Examiner
MICKLEBURGH, LINDA BOHANNON
Law office
L60
Current location
PUBLICATION AND ISSUE SECTION
Mark description
The mark consists of a series of seven parallel lines of different sizes, with the first four lines increasing in size to the fourth line and thereby decreasing in size from the fifth to the seventh lines, followed by a single vertical line next to the word "IMBRIUM" in large capital letters over the word "THERAPEUTICS" in small capital letters.
Holders and representatives
Holders
KNOA PHARMA LLC
P. L. (pessoa física)
Representatives
Fara S. Sunderji DORSEY & WHITNEY LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Pharmaceutical preparations for the treatment of central nervous system disorders
Publications
History of USPTO decisions and trademark events.
26 publications found
REM1
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
06/09/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
06/09/2020
SUNA
NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
05/08/2020
CNPR
ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
05/07/2020
DOCK
ASSIGNED TO EXAMINER
04/21/2020
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
04/21/2020
SUPC
STATEMENT OF USE PROCESSING COMPLETE
04/20/2020
DPCC
DIVISIONAL PROCESSING COMPLETE
04/20/2020
IROA
RESPONSE TO ITU OFFICE ACTION ENTERED
04/16/2020
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
04/16/2020
INCD
ITU OFFICE ACTION ISSUED FOR DIVISIONAL REQUEST
04/15/2020
AITU
CASE ASSIGNED TO INTENT TO USE PARALEGAL
04/15/2020
IUAF
USE AMENDMENT FILED
03/23/2020
DRRR
DIVISIONAL REQUEST RECEIVED
03/23/2020
EISU
TEAS STATEMENT OF USE RECEIVED
03/23/2020
ERTD
TEAS REQUEST TO DIVIDE RECEIVED
03/23/2020
NOAM
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
12/10/2019
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/15/2019
PUBO
PUBLISHED FOR OPPOSITION
10/15/2019
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
09/25/2019
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
09/06/2019
DOCK
ASSIGNED TO EXAMINER
09/05/2019
MDSC
NOTICE OF DESIGN SEARCH CODE E-MAILED
06/28/2019
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/27/2019
NWAP
NEW APPLICATION ENTERED
06/18/2019
Continuous trademark protection
Get notified about every new filing that threatens IMBRIUM THERAPEUTICS or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.